Chapter 1 16 References 1. van der Valk MJM, Hilling DE, Bastiaannet E, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391:2537–2545. 2. Kapiteijn E, Marijnen CAM, Nagtegaal ID, et al. Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer. N Engl J Med. 2001;345:638–646. 3. van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of themulticentre, randomised controlles TME trial. Lancet Oncol. 2011;12:575–582. 4. Detering R, Karthaus EG, Borstlap WAA, et al. Treatment and survival of locally recurrent rectal cancer: A cross-sectional population study 15 years after the Dutch TME trial. Eur J Surg Oncol. 2019;45:2059–2069. 5. MatsuyamaT, Yamauchi S,MasudaT, et al. Treatment and subsequent prognosis in locally recurrent rectal cancer: a multicenter retrospective study of 498 patients. Int J Colorectal Dis. 2021;36:1243– 1250. 6. Kapiteijn E, Van de Velde CJH. The role of total mesorectal excision in the management of rectal cancer. Surg Clin North Am. 2002;82:995–1007. 7. Nagtegaal ID, Velde CJH van de, Worp E van der, et al. Macroscopic Evaluation of Rectal Cancer Resection Specimen: Clinical Significance of the Pathologist in Quality Control. https://doi. org/101200/JCO200207010. 2016;20:1729–1734. 8. Kusters M, Beets GL, Van De Velde CJH, et al. A comparison between the treatment of low rectal cancer in japan and the netherlands, focusing on the patterns of local recurrence. Ann Surg. 2009;249:229–235. 9. Kusters M, Uehara K, Velde CJHV De, et al. Is There Any Reason to Still Consider Lateral Lymph Node Dissection in Rectal Cancer? Rationale and Technique. Clin Colon Rectal Surg. 2017;30:346– 356. 10. Ogura A, Konishi T, CunninghamC, et al. Neoadjuvant (chemo)radiotherapy with total mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes: Results of the multicenter lateral node study of patients with low ct3/4 rectal cancer. J Clin Oncol. 2019;37:33–43. 11. Ogura A, Konishi T, Beets GL, et al. Lateral Nodal Features on Restaging Magnetic Resonance Imaging Associated with Lateral Local Recurrence in Low Rectal Cancer after Neoadjuvant Chemoradiotherapy or Radiotherapy. JAMA Surg. 2019;154:1–8. 12. K O, S S, Y K, et al. A prospective clinical study assessing the presence of exfoliated cancer cells and rectal washout including tumors in patients who receive neoadjuvant chemoradiotherapy for rectal cancer. Surg Today. 2020;50:352–359. 13. SW, J L, SW, et al. Adverse Effects of Anastomotic Leakage on Local Recurrence and Survival After Curative Anterior Resection for Rectal Cancer: A Systematic Review and Meta-analysis. World J Surg. 2017;41:277–284. 14. Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol. 2008;26:303–312. 15. Rokan Z, Simillis C, Kontovounisios C, et al. Systematic review of classification systems for locally recurrent rectal cancer. BJS open.;5 . Epub ahead of print 2021. DOI: 10.1093/bjsopen/zrab024. 16. SuskoM, Lee J, Salama J, et al. TheUse of Re-irradiation inLocallyRecurrent, Non-metastaticRectal Cancer. Ann Surg Oncol. 2016;23:3609–3615.
RkJQdWJsaXNoZXIy MTk4NDMw